哌立福辛通过激活GSK3β抑制雷帕霉素耐药细胞的生长

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (4): 389-392.

哌立福辛通过激活GSK3β抑制雷帕霉素耐药细胞的生长

董光辉, 罗璇, 翟溯澜, 李萍, 王雪融

南京医科大学基础医学院药理学系,南京 210029,江苏

收稿日期:2011-02-21 修回日期:2011-03-12 发布日期:2011-06-22
通讯作者: 王雪融,女,教授,硕士生导师,研究方向:肿瘤药理。E-mail: wangxrnj@gmail.com
李萍,女,讲师,研究方向:肿瘤药理。E-mail: pli@njmu.edu.cn
作者简介:董光辉,男,硕士研究生,研究方向:肿瘤药理。E-mail: guanghui1111@126.com
基金资助:
国家自然科学基金(30873099);教育部科学技术研究重点项目(209050);南京医科大学引进人才科研启动基金(10RC01)

Perifosine inhibits growth of rapamycin resistant cells through activating GSK3β

DONG Guang-hui, LUO Xuan, ZHAI Su-lan, LI Ping, WANG Xue-rong

Department of Pharmacology, Nanjing Medical University, Nanjing 210029, Jiangsu, China

Received:2011-02-21 Revised:2011-03-12 Published:2011-06-22

摘要/Abstract

摘要： 目的: 研究哌立福辛对雷帕霉素耐药的非小细胞肺癌细胞株生长的抑制作用和机制。 方法: 用SRB法检测哌立福辛单用以及联用LiCl对细胞株生长的抑制作用。用Western blotting法检测哌立福辛对细胞内Akt, GSK3β信号的调控作用。 结果: 哌立福辛对雷帕霉素敏感和耐药细胞株的生长有相似的抑制作用。在耐药细胞上,哌立福辛未明显抑制Akt的磷酸化,却可以显著抑制GSK3β的磷酸化,从而激活GSK3β。用LiCl抑制GSK3β的活性可以阻断哌立福辛对耐药细胞生长的抑制作用。 结论: 哌立福辛可以通过激活GSK3β抑制雷帕霉素耐药的非小细胞肺癌细胞的生长。

关键词: 耐药性, GSK3β, 雷帕霉素, 哌立福辛

Abstract: AIM: To investigate the effects and mechanisms of perifosine on the growth of rapamcyin resistant NSCLC cells. METHODS: The growth inhibitory effects of perfisoine with or without LiCl on NSCLC cells were detected by SRB assay. The regulatory effects of perifosine on Akt, GSK3β singaling were detected by Western blotting. RESULTS: Perifosine had similar inhibitory effects on the growth of rapamycin resistant and sensitive cells. Perifosine inhibited phosphorylation of GSK3β without significant alteration of Akt phosphorylation, and thus activated GSK3β in rapamycin resistant cells. The inhibitor of GSK3β- LiCl blocked perifosine's inhibitory effects on the growth of rapamycin resistant cells. CONCLUSION: Perifosine inhibits growth of rapamycin resistant NSCLC cells through activating GSK3β.

Key words: Drug resistance, GSK3β, Rapamycin, Perifosine

中图分类号:

R965.2

董光辉, 罗璇, 翟溯澜, 李萍, 王雪融. 哌立福辛通过激活GSK3β抑制雷帕霉素耐药细胞的生长[J]. 中国临床药理学与治疗学, 2011, 16(4): 389-392.

DONG Guang-hui, LUO Xuan, ZHAI Su-lan, LI Ping, WANG Xue-rong. Perifosine inhibits growth of rapamycin resistant cells through activating GSK3β[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 389-392.

参考文献

[1] 李婧婧, 冯公侃, 朱孝峰,等. 西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响[J].中国临床药理学与治疗学, 2008, 13(7):735-739.
[2] Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of Rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation [J].Cancer Res,2008,68(18): 7409-7418.
[3] Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor[J].Curr Oncol Rep,2009,11(2): 102-110.
[4] LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations[J].Drug Resist Updat,2008,11(1/2): 32-50.
[5] 周星辉, 王丙力, 谭焕然,等.大鼠肝实质细胞原代培养模型的研究及其功能鉴定[J].中国临床药理学与治疗学,2005, 10(7):743-746.
[6] Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression[J].Cell Cycle,2003,2(4): 339-345.
[7] Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy[J].Expert Opin Ther Targets,2009,13(10): 1193-1203.
[8] Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of Rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy[J].Cancer Res,2009,69(23): 8967-8976.
[9] Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation[J].Cell Cycle,2009,8(24): 4032-4039.
[10] Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer[J].J Clin Invest,2008,118(9): 3065-3074.
[11] Wang X, Hawk N, Yue P, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy[J].Cancer Biol Ther,2008,7(12): 1952-1958.
[12] Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of Rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation[J].Mol Cell Biol,2007,27(21): 7405-7413.
[13] Abraham RT, Gibbons JJ. The mammalian target of Rapamycin signaling pathway: twists and turns in the road to cancer therapy[J].Clin Cancer Res,2007,13(11): 3109-3114.
[14] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J].N Engl J Med,2007,356(22): 2271-2281.
[15] Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by Rapamycin-mediated mammalian target of Rapamycin inhibition[J].Cancer Res,2005,65(16): 7052-7058.